propafenone has been researched along with Recrudescence in 70 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amiodarone and propafenone are commonly used to maintain sinus rhythm in patients with atrial fibrillation (AF)." | 9.34 | Comparison of Amiodarone and Propafenone in Blanking Period after Radiofrequency Catheter Ablation in Patients with Atrial Fibrillation: A Propensity Score-Matched Study. ( Chen, L; Chen, X; Fan, L; Gong, K; Huang, R; Lin, J; Xu, Z; Zhang, F; Zhang, Y, 2020) |
| "Our objective was to compare the efficacy of dronedarone and propafenone in maintaining sinus rhythm in patients with atrial fibrillation (AF) after electrical cardioversion." | 9.19 | Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion. ( Byeon, K; Chun, KJ; Im, SI; Kim, JS; On, YK; Park, KM; Park, SJ, 2014) |
| "A prospective, randomized study was conducted to evaluate the efficacy and tolerability of oral propafenone and quinidine for the conversion of paroxysmal atrial fibrillation (AF)." | 9.14 | Efficacy and tolerability of oral propafenone versus quinidine in the treatment of recent onset atrial fibrillation: A randomized, prospective study. ( Kochanowski, J; Kosior, DA; Opolski, G; Piatkowski, R; Postuła, M; Rabczenko, D; Scisło, P, 2009) |
| "This prospective, randomized, single-blinded, placebo-controlled study compared the efficacy and safety of sotalol and propafenone when used for long-term prevention of atrial fibrillation." | 9.11 | Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation. ( Chlouverakis, GI; Hamilos, ME; Igoumenidis, NE; Klapsinos, NC; Kochiadakis, GE; Tzerakis, PG; Vardas, PE, 2004) |
| "We report a double-blind, multicenter, multinational, placebo-controlled, and well-controlled trial to prove that the sustained-release (SR) formulation of propafenone is superior to placebo in preventing symptoms of paroxysmal atrial fibrillation (AF)." | 9.10 | Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). ( Camez, A; Eberle, S; Hewkin, A; Kalsch, B; Lip, GY; Lombardi, F; Meinertz, T; Sadowski, ZP, 2002) |
| "The objective of this randomized, double-blind, placebo-controlled clinical trial was to test the efficacy and safety of a new sustained-release preparation of the antiarrhythmic drug propafenone (propafenone SR) in reducing the frequency of symptomatic arrhythmia recurrences in patients with atrial fibrillation (AF)." | 9.10 | Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. ( Carlson, M; Fava, G; Page, RL; Pritchett, EL; Undesser, K, 2003) |
| "Amiodarone and propafenone were superior to sotalol in maintaining long-term normal sinus rhythm in patients with atrial fibrillation." | 9.09 | Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm? ( Chrysostomakis, SI; Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Marketou, ME; Mavrakis, HE; Vardas, PE, 2000) |
| "This study was performed to evaluate, using a randomized double-blind, placebo-controlled protocol, the long-term efficacy and safety of propafenone and sotalol in maintaining sinus rhythm after conversion of recurrent symptomatic atrial fibrillation (AF)." | 9.09 | Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. ( Bellandi, F; Dabizzi, RP; Frascarelli, F; Giovannini, T; Leoncini, M; Maioli, M; Simonetti, I, 2001) |
| "To evaluate, in a prospective and randomized fashion, the efficacy of a pretreatment with verapamil (V) in reducing recurrences of atrial fibrillation (AF) after electrical cardioversion (C)." | 9.09 | Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. ( De Matteis, C; De Simone, A; Di Napoli, T; Di Stasio, M; Gasparini, M; Petrazzuoli, F; Rotunno, R; Stabile, G; Turco, P; Vitale, DF, 1999) |
| "Propafenone, given before electrical cardioversion for chronic atrial fibrillation does not affect the mean defibrillation threshold or the rate of successful arrhythmia conversion." | 9.08 | Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. ( Bianconi, L; Castro, A; Chieffi, M; Lukic, V; Mennuni, M; Santini, M, 1996) |
| "The study consisted of a 3-month treatment with oral propafenone hydrochloride or quinidine sulphate in patients with paroxysmal symptomatic atrial fibrillation, according to a double-blind randomized system." | 9.08 | Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial. ( Chang, MS; Chen, SA; Chiang, CE; Lee, SH; Tai, CT; Wang, SP; Wen, ZC, 1996) |
| "This multicentre, randomized, double-blind study, conducted in parallel groups, was designed to compare the efficacy and safety of cibenzoline (C) and oral propafenone (P) in the prevention of recurrent atrial arrhythmias (M) over a 6-month period." | 9.08 | [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study]. ( Bleinc, D; Canler, A; Lardoux, H; Maison Blanche, P; Marchand, X; Péraudeau, P; Rouesnel, P; Scheck, F, 1996) |
| "To evaluate the efficacy of propafenone for suppression of recurrent paroxysmal symptomatic atrial fibrillation (AF), patients with frequent episodes of AF entered an open-label, dose-ranging study to determine the maximal tolerated dose of propafenone and were subsequently randomized to alternate between propafenone and placebo every month for 4 months." | 9.06 | Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. ( Connolly, SJ; Hoffert, DL, 1989) |
| "Sixteen patients with ventricular tachycardia (VT) or nonfatal cardiac arrest were treated with propafenone (P), 900 mg/day." | 9.05 | Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. ( Connolly, SJ; Echt, DS; Kates, RE; Lebsack, CS; Mason, JW; Winkle, RA, 1983) |
| "The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared." | 7.72 | Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation. ( Amit, G; Bonneh, DY; Grosbard, A; Ilia, R; Katz, A; Liss, T; Rosen, A; Wagshal, AB, 2004) |
| "The antiarrhythmic effect of oral propafenone was evaluated in 10 patients with Wolff-Parkinson-White syndrome presenting with non-ventricular arrhythmias (paroxysmal supraventricular tachycardia n = 7, atrial fibrillation or flutter n = 3)." | 7.68 | Propafenone in the prevention of non-ventricular arrhythmias associated with the Wolff-Parkinson-White syndrome. ( Kallikazaros, I; Papoutsakis, P; Stefanadis, C; Vassiliadis, I, 1990) |
| "To determine the electrophysiological properties of oral propafenone, 50 patients (39 male and 11 female, aged 31 to 80 years) with sustained ventricular tachycardia or ventricular fibrillation underwent serial electrophysiological drug testing, using propafenone (750 to 900 mg daily) as the anti-arrhythmic regimen of first choice." | 7.68 | Acute and long-term efficacy of propafenone in patients with sustained ventricular tachyarrhythmias: assessment with programmed ventricular stimulation. ( Frohner, K; Hief, C; Podczeck, A; Steinbach, KK; Stix, G, 1991) |
| "Propafenone may be effective in some patients for long term prevention of atrial fibrillation, although efficacy may decrease over time." | 7.68 | Long term efficacy of propafenone for prevention of atrial fibrillation. ( Kerr, CR; Kyles, AE; Murdock, CJ; Vorderbrugge, S; Yeung-Lai-Wah, JA, 1991) |
| "One hundred and fourteen patients were included in an open multicenter trial of the prevention of atrial arrhythmias by propafenone and of the tolerability of this anti-arrhythmic agent after a year." | 7.68 | [Efficacy and tolerance of propafenone in the prevention after a year of recurrent atrial arrhythmia. Results of a multicenter study of 114 patients]. ( Maarek-Charbit, M; Motté, G; Sirinelli, A, 1992) |
| "One hundred and ninety-six patients with stable atrial fibrillation of recent onset received propafenone (98 patients) or Amiodarone (98 patients) intravenously." | 7.68 | [The efficacy of intravenous propafenone and amiodarone in the conversion of recent-onset atrial fibrillation. A 1-year follow-up with oral treatment]. ( Bellandi, F; Cantini, F; Dabizzi, RP; Palchetti, R; Pedone, T, 1993) |
| "Electrophysiologic and hemodynamic studies were performed before and after intravenous infusion of a new antiarrhythmic agent, propafenone, in 28 patients with recurrent ventricular tachycardia." | 7.67 | Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia. ( DiCarlo, L; Morady, F; Scheinman, MM; Schwartz, AB; Shapiro, W; Shen, EN; Sung, RJ, 1984) |
| "The purpose of our study was to assess the efficacy of Propafenon in comparison with Disopyramide in the long-term treatment of repetitive ventricular tachycardia." | 7.67 | [Comparative study on the efficacy of disopyramide and propafenone in the prevention of the recurrence of ventricular tachycardia]. ( Bomba, E; Bracchetti, D; Capucci, A; Lombardi, G; Naccarella, F; Palmieri, M, 1984) |
| "The efficacy of Propafenone to prevent exercise-induced ventricular arrhythmias (EIVA) has been studied in eleven patients affected by ischemic heart disease." | 7.67 | [Effects of propafenone on arrhythmias induced by exertion in patients with ischemic cardiopathy]. ( Arrigo, F; Giannetto, M; Luzza, F; Oreto, G; Patané, S; Virga, T, 1987) |
| "Propafenone was administered to 29 patients who had multiple episodes of recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) despite previous antiarrhythmic therapy." | 7.67 | Propafenone treatment of recurrent ventricular tachycardia: comparison of continuous electrocardiographic recording and electrophysiologic study in predicting drug efficacy. ( Heger, JJ; Hubbard, J; Miles, WM; Prystowsky, EN; Zipes, DP, 1984) |
| "Sixty patients who had recurrent episodes of symptomatic atrial fibrillation or flutter, or both, and who had failed one to five prior drug trials were treated with open label oral propafenone hydrochloride." | 7.67 | Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. ( Antman, EM; Beamer, AD; Cantillon, C; Friedman, PL; Goldman, L; McGowan, N, 1988) |
| "The frequent recurrence of paroxysmal atrial fibrillation (PAF) despite the use of standard antiarrhythmic agents prompted the use of new therapeutic approaches." | 6.69 | Control of paroxysmal atrial fibrillation recurrence using combined administration of propafenone and quinidine. ( Chow, MS; Fan, C; Lau, CP; Tang, MO; Tse, HF, 2000) |
| "Amiodarone and propafenone are commonly used to maintain sinus rhythm in patients with atrial fibrillation (AF)." | 5.34 | Comparison of Amiodarone and Propafenone in Blanking Period after Radiofrequency Catheter Ablation in Patients with Atrial Fibrillation: A Propensity Score-Matched Study. ( Chen, L; Chen, X; Fan, L; Gong, K; Huang, R; Lin, J; Xu, Z; Zhang, F; Zhang, Y, 2020) |
| "Propafenone was prescribed at the initial dose of 600 mg/day in 65% of patients." | 5.31 | [Efficacy and tolerance of propafenone after correction of atrial fibrillation: PEPS pharmaco-epidemiologic study]. ( Davy, JM; Funck-Brentano, C; Jaillon, P; Mary-Krause, M; Simon, T; Weingrod, M, 2002) |
| "In our patient, recurrences of ventricular fibrillation were not prevented either by lidocaine, or amiodarone." | 5.29 | Sixty-six episodes of ventricular fibrillation within four hours: electrical stability restored by propafenone. ( Bellone, P; Spirito, P; Vecchio, C, 1994) |
| "Three patients experienced recurrence of AF in the early follow-up." | 5.29 | Role of transesophageal pacing in recurrent atrial fibrillation. Experience with propafenone. ( Bellizzi, G; Candelmo, F; Foffa, A; Guarino, P; Martino, DF; Morella, A; Parente, A; Turco, P; Viola, V, 1994) |
| "Our objective was to compare the efficacy of dronedarone and propafenone in maintaining sinus rhythm in patients with atrial fibrillation (AF) after electrical cardioversion." | 5.19 | Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion. ( Byeon, K; Chun, KJ; Im, SI; Kim, JS; On, YK; Park, KM; Park, SJ, 2014) |
| "A prospective, randomized study was conducted to evaluate the efficacy and tolerability of oral propafenone and quinidine for the conversion of paroxysmal atrial fibrillation (AF)." | 5.14 | Efficacy and tolerability of oral propafenone versus quinidine in the treatment of recent onset atrial fibrillation: A randomized, prospective study. ( Kochanowski, J; Kosior, DA; Opolski, G; Piatkowski, R; Postuła, M; Rabczenko, D; Scisło, P, 2009) |
| "This prospective, randomized, single-blinded, placebo-controlled study compared the efficacy and safety of sotalol and propafenone when used for long-term prevention of atrial fibrillation." | 5.11 | Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation. ( Chlouverakis, GI; Hamilos, ME; Igoumenidis, NE; Klapsinos, NC; Kochiadakis, GE; Tzerakis, PG; Vardas, PE, 2004) |
| "The objective of this randomized, double-blind, placebo-controlled clinical trial was to test the efficacy and safety of a new sustained-release preparation of the antiarrhythmic drug propafenone (propafenone SR) in reducing the frequency of symptomatic arrhythmia recurrences in patients with atrial fibrillation (AF)." | 5.10 | Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. ( Carlson, M; Fava, G; Page, RL; Pritchett, EL; Undesser, K, 2003) |
| "We report a double-blind, multicenter, multinational, placebo-controlled, and well-controlled trial to prove that the sustained-release (SR) formulation of propafenone is superior to placebo in preventing symptoms of paroxysmal atrial fibrillation (AF)." | 5.10 | Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). ( Camez, A; Eberle, S; Hewkin, A; Kalsch, B; Lip, GY; Lombardi, F; Meinertz, T; Sadowski, ZP, 2002) |
| "To evaluate, in a prospective and randomized fashion, the efficacy of a pretreatment with verapamil (V) in reducing recurrences of atrial fibrillation (AF) after electrical cardioversion (C)." | 5.09 | Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. ( De Matteis, C; De Simone, A; Di Napoli, T; Di Stasio, M; Gasparini, M; Petrazzuoli, F; Rotunno, R; Stabile, G; Turco, P; Vitale, DF, 1999) |
| "Amiodarone and propafenone were superior to sotalol in maintaining long-term normal sinus rhythm in patients with atrial fibrillation." | 5.09 | Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm? ( Chrysostomakis, SI; Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Marketou, ME; Mavrakis, HE; Vardas, PE, 2000) |
| "This study was performed to evaluate, using a randomized double-blind, placebo-controlled protocol, the long-term efficacy and safety of propafenone and sotalol in maintaining sinus rhythm after conversion of recurrent symptomatic atrial fibrillation (AF)." | 5.09 | Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. ( Bellandi, F; Dabizzi, RP; Frascarelli, F; Giovannini, T; Leoncini, M; Maioli, M; Simonetti, I, 2001) |
| "The study consisted of a 3-month treatment with oral propafenone hydrochloride or quinidine sulphate in patients with paroxysmal symptomatic atrial fibrillation, according to a double-blind randomized system." | 5.08 | Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial. ( Chang, MS; Chen, SA; Chiang, CE; Lee, SH; Tai, CT; Wang, SP; Wen, ZC, 1996) |
| "Propafenone, given before electrical cardioversion for chronic atrial fibrillation does not affect the mean defibrillation threshold or the rate of successful arrhythmia conversion." | 5.08 | Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. ( Bianconi, L; Castro, A; Chieffi, M; Lukic, V; Mennuni, M; Santini, M, 1996) |
| "This multicentre, randomized, double-blind study, conducted in parallel groups, was designed to compare the efficacy and safety of cibenzoline (C) and oral propafenone (P) in the prevention of recurrent atrial arrhythmias (M) over a 6-month period." | 5.08 | [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study]. ( Bleinc, D; Canler, A; Lardoux, H; Maison Blanche, P; Marchand, X; Péraudeau, P; Rouesnel, P; Scheck, F, 1996) |
| "To evaluate the efficacy of propafenone for suppression of recurrent paroxysmal symptomatic atrial fibrillation (AF), patients with frequent episodes of AF entered an open-label, dose-ranging study to determine the maximal tolerated dose of propafenone and were subsequently randomized to alternate between propafenone and placebo every month for 4 months." | 5.06 | Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. ( Connolly, SJ; Hoffert, DL, 1989) |
| "Sixteen patients with ventricular tachycardia (VT) or nonfatal cardiac arrest were treated with propafenone (P), 900 mg/day." | 5.05 | Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. ( Connolly, SJ; Echt, DS; Kates, RE; Lebsack, CS; Mason, JW; Winkle, RA, 1983) |
| "Among the drugs recommended to prevent recurrences of atrial fibrillation after external electric shock, antiarrhythmic agents of classes Ia (quinidine, disopyramide), Ic (cibenzoline, flecainide, propafenone) and III (sotalol) seem to have the same effectiveness in maintaining the sinus rhythm in about 50 percent of the cases after 6 months and one year." | 4.78 | [Antiarrhythmic treatment after reduction of atrial fibrillation by external shock]. ( Brechenmacher, C; Chauvin, M; Koenig, A; Theolade, R, 1993) |
| "The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared." | 3.72 | Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation. ( Amit, G; Bonneh, DY; Grosbard, A; Ilia, R; Katz, A; Liss, T; Rosen, A; Wagshal, AB, 2004) |
| "One hundred and ninety-six patients with stable atrial fibrillation of recent onset received propafenone (98 patients) or Amiodarone (98 patients) intravenously." | 3.68 | [The efficacy of intravenous propafenone and amiodarone in the conversion of recent-onset atrial fibrillation. A 1-year follow-up with oral treatment]. ( Bellandi, F; Cantini, F; Dabizzi, RP; Palchetti, R; Pedone, T, 1993) |
| "To determine the electrophysiological properties of oral propafenone, 50 patients (39 male and 11 female, aged 31 to 80 years) with sustained ventricular tachycardia or ventricular fibrillation underwent serial electrophysiological drug testing, using propafenone (750 to 900 mg daily) as the anti-arrhythmic regimen of first choice." | 3.68 | Acute and long-term efficacy of propafenone in patients with sustained ventricular tachyarrhythmias: assessment with programmed ventricular stimulation. ( Frohner, K; Hief, C; Podczeck, A; Steinbach, KK; Stix, G, 1991) |
| "Propafenone may be effective in some patients for long term prevention of atrial fibrillation, although efficacy may decrease over time." | 3.68 | Long term efficacy of propafenone for prevention of atrial fibrillation. ( Kerr, CR; Kyles, AE; Murdock, CJ; Vorderbrugge, S; Yeung-Lai-Wah, JA, 1991) |
| "One hundred and fourteen patients were included in an open multicenter trial of the prevention of atrial arrhythmias by propafenone and of the tolerability of this anti-arrhythmic agent after a year." | 3.68 | [Efficacy and tolerance of propafenone in the prevention after a year of recurrent atrial arrhythmia. Results of a multicenter study of 114 patients]. ( Maarek-Charbit, M; Motté, G; Sirinelli, A, 1992) |
| "In order to determine the efficacy of type 1C agents (flecainide, encainide, propafenone) in patients with atrial fibrillation who have failed to maintain sinus rhythm with type 1A agents (quinidine, procainamide, disopyramide), 147 patients, that were admitted into the John Dempsey Hospital with new or recurrent atrial fibrillation between 1987-1991, were studied retrospectively." | 3.68 | Efficacy of type 1C antiarrhythmic agents for treatment of resistant atrial fibrillation. ( Grey, E; Silverman, DI, 1993) |
| "One hundred nine patients with recurrent episodes of symptomatic atrial fibrillation or flutter, or both, who had failed one to five previous antiarrhythmic drug trials were treated with propafenone and, subsequently, sotalol if atrial fibrillation recurred." | 3.68 | Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. ( Antman, EM; Beamer, AD; Cantillon, C; Friedman, PL; McGowan, N, 1990) |
| "The antiarrhythmic effect of oral propafenone was evaluated in 10 patients with Wolff-Parkinson-White syndrome presenting with non-ventricular arrhythmias (paroxysmal supraventricular tachycardia n = 7, atrial fibrillation or flutter n = 3)." | 3.68 | Propafenone in the prevention of non-ventricular arrhythmias associated with the Wolff-Parkinson-White syndrome. ( Kallikazaros, I; Papoutsakis, P; Stefanadis, C; Vassiliadis, I, 1990) |
| "Propafenone was administered to 29 patients who had multiple episodes of recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) despite previous antiarrhythmic therapy." | 3.67 | Propafenone treatment of recurrent ventricular tachycardia: comparison of continuous electrocardiographic recording and electrophysiologic study in predicting drug efficacy. ( Heger, JJ; Hubbard, J; Miles, WM; Prystowsky, EN; Zipes, DP, 1984) |
| "The purpose of our study was to assess the efficacy of Propafenon in comparison with Disopyramide in the long-term treatment of repetitive ventricular tachycardia." | 3.67 | [Comparative study on the efficacy of disopyramide and propafenone in the prevention of the recurrence of ventricular tachycardia]. ( Bomba, E; Bracchetti, D; Capucci, A; Lombardi, G; Naccarella, F; Palmieri, M, 1984) |
| "Electrophysiologic and hemodynamic studies were performed before and after intravenous infusion of a new antiarrhythmic agent, propafenone, in 28 patients with recurrent ventricular tachycardia." | 3.67 | Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia. ( DiCarlo, L; Morady, F; Scheinman, MM; Schwartz, AB; Shapiro, W; Shen, EN; Sung, RJ, 1984) |
| "Sixty patients who had recurrent episodes of symptomatic atrial fibrillation or flutter, or both, and who had failed one to five prior drug trials were treated with open label oral propafenone hydrochloride." | 3.67 | Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. ( Antman, EM; Beamer, AD; Cantillon, C; Friedman, PL; Goldman, L; McGowan, N, 1988) |
| "The efficacy of Propafenone to prevent exercise-induced ventricular arrhythmias (EIVA) has been studied in eleven patients affected by ischemic heart disease." | 3.67 | [Effects of propafenone on arrhythmias induced by exertion in patients with ischemic cardiopathy]. ( Arrigo, F; Giannetto, M; Luzza, F; Oreto, G; Patané, S; Virga, T, 1987) |
| " Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up." | 2.73 | Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. ( Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007) |
| "However, patients with no symptomatic recurrences of AF had higher scores at 3 months on measures of global well-being than those with recurrences in the first 3 months (7." | 2.70 | Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. ( Connolly, SJ; Dorian, P; Green, M; Newman, D; Paquette, M; Roy, D; Talajic, M, 2002) |
| "The frequent recurrence of paroxysmal atrial fibrillation (PAF) despite the use of standard antiarrhythmic agents prompted the use of new therapeutic approaches." | 2.69 | Control of paroxysmal atrial fibrillation recurrence using combined administration of propafenone and quinidine. ( Chow, MS; Fan, C; Lau, CP; Tang, MO; Tse, HF, 2000) |
| "In case of PAF recurrence pts withdrew from the study." | 2.68 | [Comparison of anti-arrhythmic therapy guided by the transesophageal electropharmacologic test and emperic therapy in the prophylaxis of atrial fibrillation recurrence]. ( Burattini, M; Carunchio, A; Ceci, V; Coletta, C; Fera, MS; Galati, A; Mazza, A, 1997) |
| "The time to first recurrence was prolonged for the overall group of 23 patients while they received propafenone (P = 0." | 2.67 | Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. ( McCarthy, EA; Pritchett, EL; Wilkinson, WE, 1991) |
| "Atrial flutter is most often arising from a macroreentry circuit in the right atrium or around scar tissue in case or previous cardiothoracic surgery." | 2.43 | [Atrial flutter and fibrillation]. ( Scharf, C, 2005) |
| "Recurrence was not affected by the drug used for cardioversion (P = 0." | 1.40 | Advanced interatrial block is associated with recurrence of atrial fibrillation post pharmacological cardioversion. ( Baranchuk, A; Chiale, PA; Conde, D; de Luna, AB; Enriquez, A; Hopman, W; Mondragon, I, 2014) |
| "Propafenone was prescribed at the initial dose of 600 mg/day in 65% of patients." | 1.31 | [Efficacy and tolerance of propafenone after correction of atrial fibrillation: PEPS pharmaco-epidemiologic study]. ( Davy, JM; Funck-Brentano, C; Jaillon, P; Mary-Krause, M; Simon, T; Weingrod, M, 2002) |
| "She also developed severe arrhythmia during her hospital course." | 1.30 | Recurrent convulsions and cardiac conduction disturbances after propafenone overdose. ( Buffet, M; Grossenbacher, F; Lamiable, D; Rambourg-Schepens, MO, 1999) |
| " In this study, we prospectively investigated the effects of AFI ablation and continuation of drug therapy in patients with AF who developed AFI due to long-term administration of class IC antiarrhythmic drugs." | 1.30 | Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation. ( Jung, W; Lewalter, T; Lüderitz, B; Schumacher, B; Vahlhaus, C; Wolpert, C, 1999) |
| "In our patient, recurrences of ventricular fibrillation were not prevented either by lidocaine, or amiodarone." | 1.29 | Sixty-six episodes of ventricular fibrillation within four hours: electrical stability restored by propafenone. ( Bellone, P; Spirito, P; Vecchio, C, 1994) |
| "Three patients experienced recurrence of AF in the early follow-up." | 1.29 | Role of transesophageal pacing in recurrent atrial fibrillation. Experience with propafenone. ( Bellizzi, G; Candelmo, F; Foffa, A; Guarino, P; Martino, DF; Morella, A; Parente, A; Turco, P; Viola, V, 1994) |
| "Propafenone has been efficient in preventing supraventricular tachycardias in all patients." | 1.29 | [Propafenone efficacy in preventing supraventricular tachycardia in childhood]. ( Barrenetxea, JI; Bodegas, A; Cabrera, A; Galdeano, JM; Idígoras, G; Pastor, E; Pérez García, P; Rumoroso, JR; Sarrionaindía, MJ; Sota, J, 1994) |
| " Adverse effects were encountered in 7 patients: in 1 case worsened arrhythmia and in 6 patients, with long-lasting arrhythmias, congestive heart failure." | 1.28 | [The emergency treatment of supraventricular tachyarrhythmias: the efficacy and safety of intravenous propafenone]. ( Annoni, P; Baroffio, R; Bossi, M; Cazzaniga, L; Ciaramella, C; Guzzini, F; Maestroni, A; Tisi, G, 1992) |
| "Evaluation revealed mitral valve prolapse with minimal mitral regurgitation, and normal left ventricular size and function." | 1.28 | New onset ventricular tachycardia during pregnancy. ( Braverman, AC; Bromley, BS; Rutherford, JD, 1991) |
| "Two patients with recurrences of sustained VT in this group were later successfully treated with propafenone, 900 mg/day; overall, 8 of 9 patients with recurrences of sustained VT were successfully treated with 900 mg/day." | 1.27 | Propafenone for refractory ventricular arrhythmias: correlation with drug plasma levels during long-term treatment. ( Ambrosioni, E; Bracchetti, D; Marchesini, B; Naccarella, F; Palmieri, M, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (20.00) | 18.7374 |
| 1990's | 29 (41.43) | 18.2507 |
| 2000's | 24 (34.29) | 29.6817 |
| 2010's | 2 (2.86) | 24.3611 |
| 2020's | 1 (1.43) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, R | 1 |
| Lin, J | 1 |
| Gong, K | 1 |
| Chen, L | 1 |
| Fan, L | 1 |
| Zhang, F | 1 |
| Zhang, Y | 1 |
| Chen, X | 1 |
| Xu, Z | 1 |
| Enriquez, A | 1 |
| Conde, D | 1 |
| Hopman, W | 1 |
| Mondragon, I | 1 |
| Chiale, PA | 1 |
| de Luna, AB | 1 |
| Baranchuk, A | 1 |
| Chun, KJ | 1 |
| Byeon, K | 1 |
| Im, SI | 1 |
| Park, KM | 1 |
| Park, SJ | 1 |
| Kim, JS | 1 |
| On, YK | 1 |
| Stanaitiene, G | 1 |
| Babarskiene, RM | 1 |
| Daubert, JP | 1 |
| Kosior, DA | 1 |
| Kochanowski, J | 1 |
| Scisło, P | 1 |
| Piatkowski, R | 1 |
| Postuła, M | 1 |
| Rabczenko, D | 1 |
| Opolski, G | 1 |
| Simon, T | 1 |
| Mary-Krause, M | 1 |
| Funck-Brentano, C | 1 |
| Davy, JM | 1 |
| Weingrod, M | 1 |
| Jaillon, P | 1 |
| Meinertz, T | 1 |
| Lip, GY | 1 |
| Lombardi, F | 1 |
| Sadowski, ZP | 1 |
| Kalsch, B | 1 |
| Camez, A | 1 |
| Hewkin, A | 1 |
| Eberle, S | 1 |
| Mattioli, AV | 1 |
| Bonatti, S | 1 |
| Bonetti, L | 1 |
| Mattioli, G | 1 |
| Friberg, J | 1 |
| Gadsbøll, N | 1 |
| Pritchett, EL | 2 |
| Page, RL | 1 |
| Carlson, M | 1 |
| Undesser, K | 1 |
| Fava, G | 1 |
| Lee, JK | 2 |
| Klein, GJ | 3 |
| Krahn, AD | 2 |
| Yee, R | 2 |
| Zarnke, K | 2 |
| Simpson, C | 2 |
| Skanes, A | 2 |
| Dorian, P | 2 |
| Mangat, I | 1 |
| Amit, G | 1 |
| Rosen, A | 1 |
| Wagshal, AB | 1 |
| Bonneh, DY | 1 |
| Liss, T | 1 |
| Grosbard, A | 1 |
| Ilia, R | 1 |
| Katz, A | 1 |
| Bertaglia, E | 1 |
| Bonso, A | 1 |
| Zoppo, F | 1 |
| Proclemer, A | 1 |
| Verlato, R | 1 |
| Corò, L | 1 |
| Mantovan, R | 1 |
| Themistoclakis, S | 1 |
| Raviele, A | 1 |
| Pascotto, P | 1 |
| Kochiadakis, GE | 2 |
| Igoumenidis, NE | 2 |
| Hamilos, ME | 1 |
| Tzerakis, PG | 1 |
| Klapsinos, NC | 1 |
| Chlouverakis, GI | 1 |
| Vardas, PE | 2 |
| Scharf, C | 1 |
| Gorenek, B | 1 |
| Cavusoglu, Y | 1 |
| Goktekin, O | 1 |
| Birdane, A | 1 |
| Kudaiberdieva, G | 1 |
| Ata, N | 1 |
| Unalir, A | 1 |
| Timuralp, B | 1 |
| Janko, S | 1 |
| Hoffmann, E | 1 |
| Mykytsey, A | 1 |
| Bauman, JL | 1 |
| Razminia, M | 1 |
| Zheutlin, T | 1 |
| Wang, T | 1 |
| Saleem, M | 1 |
| Leal, S | 1 |
| Kehoe, RF | 1 |
| Connolly, SJ | 3 |
| Kates, RE | 1 |
| Lebsack, CS | 1 |
| Echt, DS | 1 |
| Mason, JW | 1 |
| Winkle, RA | 1 |
| Palmieri, M | 2 |
| Capucci, A | 1 |
| Lombardi, G | 1 |
| Naccarella, F | 2 |
| Bomba, E | 1 |
| Bracchetti, D | 2 |
| Marchesini, B | 1 |
| Ambrosioni, E | 1 |
| Heger, JJ | 1 |
| Hubbard, J | 1 |
| Zipes, DP | 1 |
| Miles, WM | 1 |
| Prystowsky, EN | 1 |
| Shen, EN | 2 |
| Sung, RJ | 2 |
| Morady, F | 2 |
| Schwartz, AB | 1 |
| Scheinman, MM | 1 |
| DiCarlo, L | 1 |
| Shapiro, W | 1 |
| Waleffe, A | 1 |
| Mary-Rabine, L | 1 |
| de Rijbel, R | 1 |
| Soyeur, D | 1 |
| Legrand, V | 1 |
| Kulbertus, HE | 1 |
| Grey, E | 1 |
| Silverman, DI | 1 |
| Siebels, J | 1 |
| Cappato, R | 1 |
| Rüppel, R | 1 |
| Schneider, MA | 1 |
| Kuck, KH | 1 |
| Reimold, SC | 2 |
| Lamas, GA | 1 |
| Cantillon, CO | 2 |
| Antman, EM | 4 |
| Alboni, P | 1 |
| Scarfò, S | 1 |
| Fucà, G | 1 |
| Paparella, N | 1 |
| Pedini, I | 1 |
| Mele, D | 1 |
| Turco, P | 2 |
| Guarino, P | 1 |
| Parente, A | 1 |
| Viola, V | 1 |
| Candelmo, F | 1 |
| Bellizzi, G | 1 |
| Foffa, A | 1 |
| Morella, A | 1 |
| Martino, DF | 1 |
| Bodegas, A | 1 |
| Cabrera, A | 1 |
| Sarrionaindía, MJ | 1 |
| Idígoras, G | 1 |
| Rumoroso, JR | 1 |
| Pérez García, P | 1 |
| Pastor, E | 1 |
| Galdeano, JM | 1 |
| Sota, J | 1 |
| Barrenetxea, JI | 1 |
| Bellone, P | 1 |
| Spirito, P | 1 |
| Vecchio, C | 1 |
| Koenig, A | 1 |
| Theolade, R | 1 |
| Chauvin, M | 1 |
| Brechenmacher, C | 1 |
| Bellandi, F | 3 |
| Cantini, F | 2 |
| Pedone, T | 1 |
| Dabizzi, RP | 3 |
| Palchetti, R | 2 |
| Friedman, PL | 3 |
| Lee, SH | 1 |
| Chen, SA | 1 |
| Chiang, CE | 1 |
| Tai, CT | 1 |
| Wen, ZC | 1 |
| Wang, SP | 1 |
| Chang, MS | 1 |
| Bianconi, L | 1 |
| Mennuni, M | 1 |
| Lukic, V | 1 |
| Castro, A | 1 |
| Chieffi, M | 1 |
| Santini, M | 1 |
| Lardoux, H | 1 |
| Maison Blanche, P | 1 |
| Marchand, X | 1 |
| Canler, A | 1 |
| Rouesnel, P | 1 |
| Bleinc, D | 1 |
| Péraudeau, P | 1 |
| Scheck, F | 1 |
| Fera, MS | 1 |
| Carunchio, A | 1 |
| Burattini, M | 1 |
| Mazza, A | 1 |
| Coletta, C | 1 |
| Galati, A | 1 |
| Ceci, V | 1 |
| Mugnaioni, G | 1 |
| Schumacher, B | 1 |
| Jung, W | 1 |
| Lewalter, T | 1 |
| Vahlhaus, C | 1 |
| Wolpert, C | 1 |
| Lüderitz, B | 1 |
| Nabar, A | 1 |
| Rodriguez, LM | 1 |
| Timmermans, C | 1 |
| Smeets, JL | 1 |
| Wellens, HJ | 1 |
| Rambourg-Schepens, MO | 1 |
| Grossenbacher, F | 1 |
| Buffet, M | 1 |
| Lamiable, D | 1 |
| De Simone, A | 1 |
| Stabile, G | 1 |
| Vitale, DF | 1 |
| Di Stasio, M | 1 |
| Petrazzuoli, F | 1 |
| Gasparini, M | 1 |
| De Matteis, C | 1 |
| Rotunno, R | 1 |
| Di Napoli, T | 1 |
| Ergene, U | 1 |
| Ergene, O | 1 |
| Fowler, J | 1 |
| Kinay, O | 1 |
| Cete, Y | 1 |
| Oktay, C | 1 |
| Nazli, C | 1 |
| Spindler, B | 1 |
| Lau, CP | 1 |
| Chow, MS | 1 |
| Tse, HF | 1 |
| Tang, MO | 1 |
| Fan, C | 1 |
| Marketou, ME | 1 |
| Chrysostomakis, SI | 1 |
| Mavrakis, HE | 1 |
| Kaleboubas, MD | 1 |
| Michelucci, A | 1 |
| Lazzeri, C | 1 |
| Padeletti, L | 1 |
| Bagliani, G | 1 |
| Colella, A | 1 |
| Sabini, A | 1 |
| Zipoli, R | 1 |
| Costoli, A | 1 |
| Pieragnoli, P | 1 |
| Gensini, GF | 1 |
| Franchi, F | 1 |
| Simonetti, I | 1 |
| Leoncini, M | 1 |
| Frascarelli, F | 1 |
| Giovannini, T | 1 |
| Maioli, M | 1 |
| Lin, JL | 1 |
| Lai, LP | 1 |
| Tseng, YZ | 1 |
| Lien, WP | 1 |
| Huang, SK | 1 |
| Paquette, M | 1 |
| Newman, D | 1 |
| Green, M | 1 |
| Talajic, M | 1 |
| Roy, D | 1 |
| Sirinelli, A | 1 |
| Maarek-Charbit, M | 1 |
| Motté, G | 1 |
| Tisi, G | 1 |
| Annoni, P | 1 |
| Baroffio, R | 1 |
| Cazzaniga, L | 1 |
| Ciaramella, C | 1 |
| Guzzini, F | 1 |
| Maestroni, A | 1 |
| Bossi, M | 1 |
| Kumagai, K | 1 |
| Yamanouchi, Y | 1 |
| Hiroki, T | 1 |
| Arakawa, K | 1 |
| Kyles, AE | 1 |
| Murdock, CJ | 1 |
| Yeung-Lai-Wah, JA | 1 |
| Vorderbrugge, S | 1 |
| Kerr, CR | 2 |
| Braverman, AC | 1 |
| Bromley, BS | 1 |
| Rutherford, JD | 1 |
| Podczeck, A | 1 |
| Frohner, K | 1 |
| Hief, C | 1 |
| Stix, G | 1 |
| Steinbach, KK | 1 |
| McCarthy, EA | 1 |
| Wilkinson, WE | 1 |
| Beamer, AD | 2 |
| Cantillon, C | 2 |
| McGowan, N | 2 |
| Vassiliadis, I | 1 |
| Papoutsakis, P | 1 |
| Kallikazaros, I | 1 |
| Stefanadis, C | 1 |
| Menozzi, C | 1 |
| Brignole, M | 1 |
| Monducci, I | 1 |
| Lolli, G | 1 |
| Hoffert, DL | 1 |
| Musto, B | 1 |
| D'Onofrio, A | 1 |
| Cavallaro, C | 1 |
| Musto, A | 1 |
| Axelson, JE | 1 |
| Cooper, JC | 1 |
| Marchlinski, FE | 1 |
| Goldman, L | 1 |
| Patané, S | 1 |
| Virga, T | 1 |
| Giannetto, M | 1 |
| Luzza, F | 1 |
| Oreto, G | 1 |
| Arrigo, F | 1 |
| Keung, E | 1 |
| Huycke, E | 1 |
| Dohrmann, ML | 1 |
| Nguyen, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation After DC Cardioversion[NCT01991119] | 98 participants (Actual) | Interventional | 2011-05-31 | Completed | |||
| First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation - a Randomized Study Comparing Early Trigger Isolation Using the Cryoballoon Versus Antiarrhythmic Medication[NCT05939076] | Phase 3 | 220 participants (Anticipated) | Interventional | 2023-08-21 | Not yet recruiting | ||
| Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation[NCT02145546] | Phase 4 | 600 participants (Anticipated) | Interventional | 2014-05-31 | Not yet recruiting | ||
| Home-based Videoplethysmographic Detection of Atrial Fibrillation[NCT04267133] | 256 participants (Actual) | Interventional | 2018-05-24 | Completed | |||
| Subclinical Postoperative Atrial Fibrillation[NCT02522364] | 150 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | |||
| [NCT00005237] | 0 participants | Observational | 1988-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The outcome measure is the AUC of the curve obtained from the ROC analysis. The curve is a combination of specificity and sensitivity of detecting atrial fibrillation. The range of the curve is 0.5-1.0 where 0.5 would be random detection of atrial fibrillation and 1.0 would be perfect performance. (NCT04267133)
Timeframe: 2 weeks
| Intervention | probability (Number) |
|---|---|
| All Participants | 0.74 |
3 reviews available for propafenone and Recrudescence
| Article | Year |
|---|---|
[Atrial flutter and fibrillation].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia | 2005 |
[Drug treatment of atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti | 2006 |
[Antiarrhythmic treatment after reduction of atrial fibrillation by external shock].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Disopyramide; El | 1993 |
30 trials available for propafenone and Recrudescence
| Article | Year |
|---|---|
Comparison of Amiodarone and Propafenone in Blanking Period after Radiofrequency Catheter Ablation in Patients with Atrial Fibrillation: A Propensity Score-Matched Study.
Topics: Aged; Amiodarone; Atrial Fibrillation; Catheter Ablation; Female; Humans; Male; Middle Aged; Propafe | 2020 |
Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Dronedaron | 2014 |
Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Dronedaron | 2014 |
Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Dronedaron | 2014 |
Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Dronedaron | 2014 |
[Impact of electrical shock waveform and paddle positions on efficacy of direct current cardioversion for atrial fibrillation].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Mass Index; Chi-Square Distribut | 2008 |
Efficacy and tolerability of oral propafenone versus quinidine in the treatment of recent onset atrial fibrillation: A randomized, prospective study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; B | 2009 |
Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study).
Topics: Acute Disease; Anti-Arrhythmia Agents; Atrial Fibrillation; Delayed-Action Preparations; Double-Blin | 2002 |
Left atrial size after cardioversion for atrial fibrillation: effect of external direct current shock.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function, Left; Blood Flow Velocity | 2003 |
Intracardiac low-energy versus transthoracic high-energy direct-current cardioversion of atrial fibrillation: a randomised comparison.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Creatine Kinase; Electric | 2003 |
Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; C | 2003 |
Rate-control versus conversion strategy in postoperative atrial fibrillation: trial design and pilot study results.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fib | 2003 |
Quality of life variables in the selection of rate versus rhythm control in patients with atrial fibrillation: observations from the Canadian Trial of Atrial Fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Health Status Indicators; Humans; Propafeno | 2003 |
Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Middle Aged; Propafenone; P | 2004 |
Amiodarone versus Sotalol and Propafenone for prevention of immediate recurrence of atrial fibrillation after internal cardioversion: importance of P wave analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Humans; Male | 2006 |
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2007 |
Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Cardiac Catheterization; Cardiac Pacing, Artificial; C | 1983 |
ICD versus drugs in cardiac arrest survivors: preliminary results of the Cardiac Arrest Study Hamburg.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable | 1993 |
Risk factors for the development of recurrent atrial fibrillation: role of pacing and clinical variables.
Topics: Atrial Fibrillation; Cardiac Pacing, Artificial; Chronic Disease; Female; Heart Atria; Heart Disease | 1995 |
Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Humans; Male; | 1993 |
Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Electrocardi | 1996 |
Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Chron | 1996 |
[Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study].
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation | 1996 |
[Comparison of anti-arrhythmic therapy guided by the transesophageal electropharmacologic test and emperic therapy in the prophylaxis of atrial fibrillation recurrence].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography, Transesophageal; Female; Flecainide; | 1997 |
Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Combined Modality Therapy; Elect | 1999 |
Rate-control versus conversion strategy in postoperative atrial fibrillation: a prospective, randomized pilot study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Digoxin; | 2000 |
Control of paroxysmal atrial fibrillation recurrence using combined administration of propafenone and quinidine.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Cross-Ov | 2000 |
Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Heart R | 2000 |
Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Surviva | 2001 |
Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Female; Health Status Indicat | 2002 |
Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Dose-Response Relationship, Drug; Female; Follo | 1991 |
Usefulness of propafenone for recurrent paroxysmal atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Double-Blind Method; Humans; | 1989 |
Intravenous propafenone for termination of reentrant supraventricular tachycardia. A placebo-controlled, randomized, double-blind, crossover study.
Topics: Adult; Aged; Double-Blind Method; Drug Evaluation; Electrocardiography; Humans; Injections, Intraven | 1986 |
37 other studies available for propafenone and Recrudescence
| Article | Year |
|---|---|
Advanced interatrial block is associated with recurrence of atrial fibrillation post pharmacological cardioversion.
Topics: Aged; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Electrocardiogra | 2014 |
Is newer better? Propafenone versus quinidine for conversion of atrial fibrillation.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Drug Therapy, Combinatio | 2009 |
[Efficacy and tolerance of propafenone after correction of atrial fibrillation: PEPS pharmaco-epidemiologic study].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Female; Humans; Male; Middle Aged | 2002 |
Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Drugs, Generic | 2004 |
Different clinical courses and predictors of atrial fibrillation occurrence after transisthmic ablation in patients with preablation lone atrial flutter, coexistent atrial fibrillation, and drug induced atrial flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Co | 2004 |
[Comparative study on the efficacy of disopyramide and propafenone in the prevention of the recurrence of ventricular tachycardia].
Topics: Anti-Arrhythmia Agents; Disopyramide; Drug Evaluation; Heart Ventricles; Humans; Propafenone; Propio | 1984 |
Propafenone for refractory ventricular arrhythmias: correlation with drug plasma levels during long-term treatment.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Chromatography, High Pressure Liquid; Dizziness; Female; Humans | 1984 |
Propafenone treatment of recurrent ventricular tachycardia: comparison of continuous electrocardiographic recording and electrophysiologic study in predicting drug efficacy.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography; Female; Humans | 1984 |
Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Electrophysiology; Female; Heart Conduction System; | 1984 |
Electrophysiological effects of propafenone studied with programmed electrical stimulation of the heart in patients with recurrent paroxysmal supraventricular tachycardia.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Electric Stimulation; Female; Heart; Hear | 1981 |
Efficacy of type 1C antiarrhythmic agents for treatment of resistant atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Encainide; Female; Flecainide; Hear | 1993 |
Hemodynamic effects of oral propafenone during both sinus rhythm and atrial fibrillation.
Topics: Administration, Oral; Atrial Fibrillation; Electrophysiology; Female; Heart Rate; Hemodynamics; Huma | 1995 |
Role of transesophageal pacing in recurrent atrial fibrillation. Experience with propafenone.
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Cardiac Pacing, Artificial; Echocardiography | 1994 |
[Propafenone efficacy in preventing supraventricular tachycardia in childhood].
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Drug Evaluation; Echocardiography, Dopple | 1994 |
Sixty-six episodes of ventricular fibrillation within four hours: electrical stability restored by propafenone.
Topics: Amiodarone; Electric Countershock; Humans; Injections, Intravenous; Lidocaine; Male; Middle Aged; My | 1994 |
[The efficacy of intravenous propafenone and amiodarone in the conversion of recent-onset atrial fibrillation. A 1-year follow-up with oral treatment].
Topics: Administration, Oral; Adult; Aged; Amiodarone; Atrial Fibrillation; Drug Evaluation; Female; Follow- | 1993 |
[Pharmacological cardioversion of isolated atrial fibrillation: recovery of atrial mechanical function and correlation with duration of arrhythmia].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Data Interpretation, Stat | 1997 |
Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation | 1999 |
Radiofrequency ablation of "class IC atrial flutter" in patients with resistant atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cath | 1999 |
Recurrent convulsions and cardiac conduction disturbances after propafenone overdose.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Conduction System; Humans; Propaf | 1999 |
Must antidysrhythmic agents be given to all patients with new-onset atrial fibrillation?
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Monitoring; Emergency | 1999 |
Altered values of heart rate variability in patients with relapse of atrial fibrillation during the first week after electrical cardioversion: preliminary data.
Topics: Aged; Amiodarone; Atrial Fibrillation; Circadian Rhythm; Electric Countershock; Electrocardiography, | 2001 |
Global distribution of atrial ectopic foci triggering recurrence of atrial tachyarrhythmia after electrical cardioversion of long-standing atrial fibrillation: a bi-atrial basket mapping study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; | 2001 |
[Efficacy and tolerance of propafenone in the prevention after a year of recurrent atrial arrhythmia. Results of a multicenter study of 114 patients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Blood Pressure; Drug Tolerance; El | 1992 |
[The emergency treatment of supraventricular tachyarrhythmias: the efficacy and safety of intravenous propafenone].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Drug Evaluation; Emergencies; F | 1992 |
Effects of transcatheter cardioversion on chronic lone atrial fibrillation.
Topics: Atrial Fibrillation; Cardiac Catheterization; Cardiac Pacing, Artificial; Chronic Disease; Disopyram | 1991 |
Long term efficacy of propafenone for prevention of atrial fibrillation.
Topics: Atrial Fibrillation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Propafenone; Recurrence; | 1991 |
New onset ventricular tachycardia during pregnancy.
Topics: Adult; Electrocardiography; Electrophysiology; Female; Humans; Mitral Valve Insufficiency; Mitral Va | 1991 |
Acute and long-term efficacy of propafenone in patients with sustained ventricular tachyarrhythmias: assessment with programmed ventricular stimulation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Coronary Disease; Drug Evaluation; Electric St | 1991 |
Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs.
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Data Interpretation, Statistical; Drug Administrat | 1990 |
Propafenone in the prevention of non-ventricular arrhythmias associated with the Wolff-Parkinson-White syndrome.
Topics: Adult; Atrial Fibrillation; Drug Administration Schedule; Echocardiography; Electrocardiography; Ele | 1990 |
Noninvasive serial electrophysiological testing using an implanted pacemaker for management of recurrent ventricular tachycardia.
Topics: Aged; Amiodarone; Electrophysiology; Heart Ventricles; Humans; Male; Mexiletine; Pacemaker, Artifici | 1986 |
Electrophysiological effects and clinical efficacy of propafenone in children with recurrent paroxysmal supraventricular tachycardia.
Topics: Cardiac Pacing, Artificial; Child; Electrocardiography; Electrophysiology; Female; Follow-Up Studies | 1988 |
Propafenone for prevention of recurrent atrial fibrillation.
Topics: Adult; Aged; Atrial Fibrillation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Propafenone; | 1988 |
Propafenone: new therapy for a tough, old arrhythmia.
Topics: Atrial Fibrillation; Atrial Flutter; Electric Countershock; Humans; Propafenone; Recurrence | 1988 |
Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter.
Topics: Actuarial Analysis; Administration, Oral; Atrial Fibrillation; Atrial Flutter; Female; Humans; Male; | 1988 |
[Effects of propafenone on arrhythmias induced by exertion in patients with ischemic cardiopathy].
Topics: Aged; Arrhythmias, Cardiac; Coronary Disease; Electrocardiography; Heart Ventricles; Humans; Male; M | 1987 |